|
NEW TESTS
Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. |
|||
|---|---|---|---|
| Test Code | Test Name | Effective Date | Page # |
| 16212 | Anaplasma phagocytophilum and E.chaffeensis Antibody Panel Reflex to Titers | 1/26/2026 | |
| 16189 | Anaplasma phagocytophilum Antibodies (IgG, IgM) with Reflex to Titers | 1/26/2026 | |
| 16194 | Babesia microti Antibodies (IgG, IgM) with Reflex to Titers | 1/26/2026 | |
| 16197 | Ehrlichia chaffeensis Antibodies (IgG, IgM) with Reflex to Titers | 1/26/2026 | |
| 16220 | Tick-Borne Disease Antibodies Panel with Reflexes | 1/26/2026 | |
|
TEST CHANGES
Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. |
||||
|---|---|---|---|---|
| Test Code | Former Test Code | Test Name | Effective Date | Page # |
| 39733 | Lyme Disease Antibody with Reflex to Immunoassay (IgG, IgM) (MTTT) | 1/26/2026 | ||
|
DISCONTINUED TESTS
Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. |
|||
|---|---|---|---|
| Test Code | Test Name | Effective Date | Page # |
| 10611 | Anaplasma phagocytophilum and Ehrlichia chaffeensis Antibody Panel | 1/26/2026 | |
| 34464 | Anaplasma phagocytophilum Antibodies (IgG, IgM) | 1/26/2026 | |
| 34300 | Babesia microti Antibodies (IgG, IgM), IFA | 1/26/2026 | |
| 34271 | Ehrlichia chaffeensis (IgG, IgM) | 1/26/2026 | |
| 36942 | Tick-Borne Disease, Antibody Panel | 1/26/2026 | |
Note: It may be 24 - 48 hours after the published effective date before this test information is available on the Online Test Directory or in Quanum™.
Patient Informed Consent
Quest Diagnostics is announcing a new way for providers to confirm that patient informed consent was obtained for genetic testing where required by applicable law. This confirmation is required for certain genetic tests if the ordering provider is located in AK, AZ, DE, FL, GA, IA, MA, MN, MT, NV, NH, NJ, NY, OR, SC, SD, or VT or testing is performed in MA. Beginning 12.1.2025 you can add test code 1315 ‘Confirmation of Patient Informed Consent for Genetic Testing’ to orders with genetic test codes to satisfy this requirement. To see which genetic tests have this requirement, visit https://testdirectory.questdiagnostics.com and search for ‘informed consent’ (search feature also avail 12.1.2025).
Tick-Borne Diseases
Quest Diagnostics is pleased to announce the incorporation of the Lyme modified two-tiered testing (MTTT) into our Tick-Borne Disease, Antibody Panel. MTTT is part of an updated recommendation from the CDC for detection and diagnosis of Lyme disease. It utilizes immunoassays rather than immunoblots in the second tier of the algorithm and may be able to assist in the identification of early Lyme disease in the first 30 days of infection. This better aligns with client testing needs.
The following tests will be available through Quest Diagnostics on the dates indicated below.
| Anaplasma phagocytophilum and E.chaffeensis Antibody Panel Reflex to Titers | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Significance |
This panel is for the detection of IgG and IgM antibodies against Anaplasma phagocytophilum and Ehrlichia chaffeensis. Anaplasmosis (human granulocytic anaplasmosis) and Ehrlichiosis (human monocytic ehrlichiosis) are tickborne diseases caused by transmission of the bacteria via the bite of an infected tick. Anaplasmosis is most common in the Northeastern and upper Midwestern United States. Ehrlichiosis is most common in the eastern, southeastern and south-central United States. Testing for tickborne disease is based on a clinical evaluation and risk of tick exposure with consideration to the geographic region. Symptoms may be nonspecific, including headache, fever/chills, malaise, myalgia, gastrointestinal symptoms, and rash. Infection can have similarities with other tickborne illnesses with overlapping vectors, geographic endemicity, and similar clinical signs and symptoms, including Borrelia burgdorferi (Lyme disease) and Babesia microti. Negative results can occur early in infection. Nucleic acid amplification tests are the preferred method for diagnosis during acute infection. Seroconversion or a four-fold increase between acute and convalescent sera can be used to support a diagnosis. The presence of IgG alone may indicate past infection, and IgM may persist for many months after infection has resolved. Antibody levels may remain elevated for several years after acute illness. Cross-reactivity between Anaplasma and Ehrlichia spp can occur. Therefore, interpretation of serologic results is done in the context of pertinent clinical picture, including timing from symptom onset. References: 1. Tickborne Diseases of the United States. A Reference Manual for Healthcare Providers, Sixth Edition, 2022. Centers for Disease Control and Prevention. 2. Clinical Testing and Diagnosis for Anaplasmosis. Centers for Disease Control and Prevention. Last updated May 15, 2024. < https://www.cdc.gov/anaplasmosis/hcp/diagnosis-testing/index.html> 3. Miller, MJ, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. 2024 Mar 5:ciae104.doi: 10.1093/cid/ciae104. 4. Biggs, HM, et al. Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. MMWR Recomm Rep. 2016 May 13;65(2):1-44. 5. Clinical Testing and Diagnosis for Ehrlichiosis. Centers for Disease Control and Prevention. Last updated May 15, 2024. < https://www.cdc.gov/ehrlichiosis/hcp/diagnosis-testing/index.html> |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Effective Date | 1/26/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Test Code | 16212 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CPT Codes | 86666 (x4) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Requirements | 1 mL (0.4 mL minimum) serum | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transport Temperature | Room temperature | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Stability |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reference Range |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Methodology | Immunofluorescence Assay | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Performing Site | Quest Diagnostics (IFD) San Juan Capistrano | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interface Mapping |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional Information |
If A. phagocytophilum (IgG) is Detected, then A. phagocytophilum (IgG) Titer will be performed at an additional charge (CPT code(s): 86666). If A. phagocytophilum (IgM) is Detected, then A. phagocytophilum (IgM) Titer will be performed at an additional charge (CPT code(s): 86666). If E. chaffeensis (IgG) is Detected, then E. chaffeensis (IgG) Titer will be performed at an additional charge (CPT code(s): 86666). If E. chaffeensis (IgM) is Detected, then E. chaffeensis (IgM) Titer will be performed at an additional charge (CPT code(s): 86666). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anaplasma phagocytophilum Antibodies (IgG, IgM) with Reflex to Titers | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Significance |
This test is for the detection of IgG and IgM antibodies against Anaplasma phagocytophilum to aid in the diagnosis of Anaplasmosis (human granulocytic anaplasmosis). Anaplasmosis is a tickborne disease caused by transmission of the bacteria via the bite of an infected tick. It is most common in the Northeastern and upper Midwestern United States during warmer months. Testing for Anaplasmosis is based on a clinical evaluation and risk of tick exposure with consideration to the geographic region. Symptoms may be nonspecific, including headache, fever/chills, malaise, myalgia, gastrointestinal symptoms, and rash (less common). Infection can have similarities with other tickborne illnesses with overlapping vectors, geographic endemicity, and similar clinical signs and symptoms, including Ehrlichia spp, Borrelia burgdorferi (Lyme disease) and Babesia microti. Negative results can occur early in infection. Nucleic acid amplification tests are the preferred method for diagnosis during acute infection. Seroconversion or a four-fold increase between acute and convalescent sera can be used to support a diagnosis. The presence of IgG alone may indicate past infection, and IgM may persist for many months after infection has resolved. Antibody levels may remain elevated for several years after acute illness. Cross-reactivity between related organisms Anaplasma and Ehrlichia spp, can occur. Therefore, interpretation of serologic results is done in the context of pertinent clinical picture, including timing from symptom onset. References: 1. Tickborne Diseases of the United States. A Reference Manual for Healthcare Providers, Sixth Edition, 2022. Centers for Disease Control and Prevention. 2. Clinical Testing and Diagnosis for Anaplasmosis. Centers for Disease Control and Prevention. Last updated May 15, 2024. < https://www.cdc.gov/anaplasmosis/hcp/diagnosis-testing/index.html> 3. Miller, MJ, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. 2024 Mar 5:ciae104.doi: 10.1093/cid/ciae104. 4. Biggs, HM, et al. Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. MMWR Recomm Rep. 2016 May 13;65(2):1-44. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Effective Date | 1/26/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Test Code | 16189 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CPT Codes | 86666 (x2) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Requirements | 1 mL (0.2 mL minimum) serum | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transport Temperature | Room temperature | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Stability |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Set-up/Analytic Time | Set up: Mon, Wed-Sat; Report available 1-3 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reference Range |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Methodology | Immunofluorescence Assay | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Performing Site | Quest Diagnostics (IFD) San Juan Capistrano | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interface Mapping |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional Information |
If A. phagocytophilum (IgG) is Detected, then A. phagocytophilum (IgG) Titer will be performed at an additional charge (CPT code(s): 86666). If A. phagocytophilum (IgM) is Detected, then A. phagocytophilum (IgM) Titer will be performed at an additional charge (CPT code(s): 86666). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Babesia microti Antibodies (IgG, IgM) with Reflex to Titers | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Significance |
This test is for the detection of IgG and IgM antibodies against Babesia microti to aid in the diagnosis of Babesiosis. Babesiosis is a tickborne disease caused by transmission of the protozoa via the bite of an infected tick. B. microti is most common in the northern and upper Midwestern United States. Testing for B. microti is based on a clinical evaluation and risk of tick exposure with consideration to the geographic region. Symptoms may be nonspecific, including headache, fever/chills, malaise, myalgia, and gastrointestinal symptoms. Infection can have similarities with other tickborne illnesses with overlapping vectors, geographic endemicity, and similar clinical signs and symptoms, including Anaplasma spp, Ehrlichia spp, and Borrelia burgdorferi (Lyme disease). Negative results can occur early in infection. Nucleic acid amplification tests are the preferred method for diagnosis during acute infection. Seroconversion or a four-fold increase between acute and convalescent sera can be used to support a diagnosis. The presence of IgG alone may indicate past infection, and IgM may persist for many months after infection has resolved. Antibody levels may remain elevated for several years after acute illness. Other less common Babesia species in different geographic regions have been identified to infect humans, such as B. duncani and B. divergens. The extent of cross-reactivity between Babesia species is variable and may not be detected by this assay. Therefore, interpretation of serologic results is done in the context of pertinent clinical picture, including timing from symptom onset. References: 1. Tickborne Diseases of the United States. A Reference Manual for Healthcare Providers, Sixth Edition, 2022. Centers for Disease Control and Prevention. 2. Clinical Testing and Diagnosis for Ehrlichiosis. Centers for Disease Control and Prevention. Last updated May 15, 2024. < https://www.cdc.gov/ehrlichiosis/hcp/diagnosis-testing/index.html> 3. Krause, PJ. et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clin Infect Dis. 2021 Jan 27;72(2):e49-e64. doi: 10.1093/cid/ciaa1216. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Effective Date | 1/26/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Test Code | 16194 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CPT Codes | 86753 (x2) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Requirements | 1 mL (0.2 mL minimum) serum | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transport Temperature | Refrigerated | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Stability |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Set-up/Analytic Time | Set up: Mon, Wed-Sat; Report available 1-3 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reference Range |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Methodology | Immunofluorescence Assay | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Performing Site | Quest Diagnostics (IFD) San Juan Capistrano | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interface Mapping |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional Information |
If B. microti (IgG) is Detected, then B. microti (IgG) Titer will be performed at an additional charge (CPT code(s): 86753). If B. microti (IgM) is Detected, then B. microti (IgM) Titer will be performed at an additional charge (CPT code(s): 86753). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ehrlichia chaffeensis Antibodies (IgG, IgM) with Reflex to Titers | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Significance |
This test is for the detection of IgG and IgM antibodies against Ehrlichia chaffeensis to aid in the diagnosis of Ehrlichiosis (human monocytic ehrlichiosis). Ehrlichiosis is a tickborne disease caused by transmission of the bacteria via the bite of an infected tick. It is most common in the eastern to southeastern and south-central United States. Testing for E. chaffeensis is based on a clinical evaluation and risk of tick exposure with consideration to the geographic region. Symptoms may be nonspecific, including headache, fever/chills, malaise, myalgia, gastrointestinal symptoms, and rash. Infection can have similarities with other tickborne illnesses with overlapping vectors, geographic endemicity, and similar clinical signs and symptoms, including Anaplasma spp, Borrelia burgdorferi (Lyme disease) and Babesia microti. Negative results can occur early in infection. Nucleic acid amplification tests are the preferred method for diagnosis during acute infection. Seroconversion or a four-fold increase between acute and convalescent sera can be used to support a diagnosis. The presence of IgG alone may indicate past infection, and IgM may persist for many months after infection has resolved. Antibody levels may remain elevated for several years after acute illness. Cross-reactivity between related organisms Anaplasma and Ehrlichia spp, can occur. Therefore, interpretation of serologic results is done in the context of pertinent clinical picture, including timing from symptom onset. References 1. Tickborne Diseases of the United States. A Reference Manual for Healthcare Providers, Sixth Edition, 2022. Centers for Disease Control and Prevention. 2. Clinical Testing and Diagnosis for Ehrlichiosis. Centers for Disease Control and Prevention. Last updated May 15, 2024. < https://www.cdc.gov/ehrlichiosis/hcp/diagnosis-testing/index.html> 3. Miller, MJ. Et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. 2024 Mar 5:ciae104.doi: 10.1093/cid/ciae104. 4. Biggs, HM, et al. Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. MMWR Recomm Rep. 2016 May 13;65(2):1-44. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Effective Date | 1/26/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Test Code | 16197 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CPT Codes | 86666 (x2) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Requirements | 1 mL (0.2 mL minimum) serum | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transport Temperature | Room temperature | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Stability |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Set-up/Analytic Time | Set up: Mon, Wed-Sat; Report available 1-3 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reference Range |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Methodology | Immunofluorescence Assay | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Performing Site | Quest Diagnostics (IFD) San Juan Capistrano | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interface Mapping |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional Information |
If E. chaffeensis (IgG) is Detected, then E. chaffeensis (IgG) Titer will be performed at an additional charge (CPT code(s): 86666). If E. chaffeensis (IgM) is Detected, then E. chaffeensis (IgM) Titer will be performed at an additional charge (CPT code(s): 86666). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tick-Borne Disease Antibodies Panel with Reflexes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Significance |
This panel contains components for the detection of antibodies against Borrelia burgdorferi (Lyme disease) using the modified two-tier algorithm, Anaplasma phagocytophilum, Ehrlichia chaffeensis, and Babesia microti. Infection with these organisms can occur from the bite of a tick found in endemic regions, including the upper Northeast and Midwestern United States. Appropriate reflex testing of individual components is performed for initial screen results. The tests included in the panel are serologic assays used to aid in the diagnosis of select tickborne related illnesses. Testing for tickborne diseases is based on a clinical evaluation and risk of tick exposure with consideration to the geographic region of potential exposure. Symptoms may be nonspecific, including fever/chills, muscle aches, fatigue, and rash. Although infections may have a distinctive rash, some may be undifferentiated or atypical. These infections often have overlapping vectors, geographic endemicity, and similar clinical signs and symptoms. In some cases, co-infection can occur. Therefore, it is suggested that testing for multiple pathogens in the same endemic region be considered. Testing of IgG and IgM are included for individual components. Negative results can occur early in infection. Seroconversion or a four-fold increase between acute and convalescent sera can be used to support a diagnosis. The presence of IgG alone may indicate past infection and IgM in some cases may persist for many months after infection has resolved. Cross-reactivity between related organisms, such as Anaplasma and Ehrlichia, can occur. Therefore, interpretation of serologic results is done in the context of pertinent clinical picture, including timing from symptom onset. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Effective Date | 1/26/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Test Code | 16220 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CPT Codes | 86666 (x2), 86753 (x2), 86618, 86666 (x2) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Requirements | 2 mL (1.5 minimum) serum | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transport Temperature | Refrigerated | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Stability |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Set-up/Analytic Time | See individual tests | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reference Range |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Methodology | See Individual Assays | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Performing Site | Quest Diagnostics (IFD) San Juan Capistrano | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interface Mapping |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional Information |
If Lyme Disease Antibody is Positive or Equivocal (> or = 0.90), then Lyme Disease Supplemental Antibodies (IgG, IgM), Immunoassay will be performed at an additional charge (CPT code(s): 86617(x2)) If A. phagocytophilum (IgG) is Detected, then A. phagocytophilum (IgG) Titer will be performed at an additional charge (CPT code(s): 86666). If A. phagocytophilum (IgM) is Detected, then A. phagocytophilum (IgM) Titer will be performed at an additional charge (CPT code(s): 86666). If B. microti (IgG) is Detected, then B. microti (IgG) Titer will be performed at an additional charge (CPT code(s): 86753). If B. microti (IgM) is Detected, then B. microti (IgM) Titer will be performed at an additional charge (CPT code(s): 86753). If E. chaffeensis (IgG) is Detected, then E. chaffeensis (IgG) Titer will be performed at an additional charge (CPT code(s): 86666). If E. chaffeensis (IgM) is Detected, then E. chaffeensis (IgM) Titer will be performed at an additional charge (CPT code(s): 86666). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The following test changes will be effective on the dates indicated below. Please note information that is changing appears in bold text in this update. Former test names and test codes have been italicized.
| Lyme Disease Antibody with Reflex to Immunoassay (IgG, IgM) (MTTT) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Significance |
This test is for the qualitative detection of antibodies against Borrelia burgdorferi, the causative agent of Lyme disease, using the modified two-tier testing (MTTT) algorithm. Initial testing is performed using a Lyme total (IgG and IgM) antibody assay and if positive or equivocal, the sample is then tested using separate IgG and IgM immunoassays. This algorithm differs from the STTT algorithm in that the second-tier assays are chemiluminescent immunoassays, not immunoblots. MTTT may be able to assist in the identification of Lyme disease with improved sensitivity earlier in infection compared to STTT. Diagnostic testing for Lyme disease relies on a two-step algorithm to increase sensitivity and specificity. Testing is performed in patients presenting with signs and symptoms consistent with Lyme disease and with potential tick exposure in endemic regions. Most infections are transmitted by blacklegged ticks in the upper midwestern, northeastern, and mid-Atlantic states. Negative results can occur in patient with recent infection (< or = 14 days). In persons with recent or past infection, both IgG and IgM can be detectable months to years after the infection has resolved. Therefore, it is recommended to interpret results in the context of the clinical picture, history, including exposure risk, and symptom onset. 1. Mead, P. et al. Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease. Wkly Rep. 2019 Aug 16;68(32):703. doi: 10.15585/mmwr.mm6832a4. 2. Suggested Reporting Language, Interpretation and Guidance For Lyme Disease Serologic Test Results. Association of Public Health Laboratories. April 2024. 3. Sfeir MM, Meece JK, Theel ES, et al. Multicenter clinical evaluation of modified two-tiered testing algorithms for Lyme disease using zeus scientific commercial assays. J Clin Microbiol 2022; 60:e0252821. 4. Tickborne Diseases of the United States. A Reference Manual for Healthcare Providers, Sixth Edition, 2022. Centers for Disease Control and Prevention. 7/8/25 updated symbols VR |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Effective Date | 1/26/2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Former Test Name | Lyme Disease Antibody with Reflex to Immunoassay (IgG, IgM) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Test Code | 39733 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Stability |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reference Range |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Performing Site | Quest Diagnostics (IFD) San Juan Capistrano | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interface Mapping |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional Information | If Lyme Disease Antibody is Positive or Equivocal (> or = 0.90), then Lyme Disease Supplemental Antibodies (IgG, IgM), Immunoassay will be performed at an additional charge (CPT code(s): 86617(x2)) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anaplasma phagocytophilum and Ehrlichia chaffeensis Antibody Panel | |
|---|---|
| Effective Date | 1/26/2026 |
| Test Code | 10611 |
| Additional Information |
The recommended alternative is test code-16212 Anaplasma phagocytophilum and E.chaffeensis Antibody Panel Reflex to Titers Please note: this code is contained in custom panels |
| Anaplasma phagocytophilum Antibodies (IgG, IgM) | |
|---|---|
| Effective Date | 1/26/2026 |
| Test Code | 34464 |
| Additional Information |
The recommended alternative is test code-16189 Anaplasma phagocytophilum Antibodies (IgG, IgM) with Reflex to Titers Please note: this code is contained in custom panels |
| Babesia microti Antibodies (IgG, IgM), IFA | |
|---|---|
| Effective Date | 1/26/2026 |
| Test Code | 34300 |
| Additional Information |
The recommended alternative is test code-16194 Babesia microti Antibodies (IgG, IgM) with Reflex to Titers Please note: this code is contained in custom panels |
| Ehrlichia chaffeensis (IgG, IgM) | |
|---|---|
| Effective Date | 1/26/2026 |
| Test Code | 34271 |
| Additional Information |
The recommended alternative is test code-16197 Ehrlichia chaffeensis Antibodies (IgG, IgM) with Reflex to Titers Please note: this code is contained in custom panels |
| Tick-Borne Disease, Antibody Panel | |
|---|---|
| Effective Date | 1/26/2026 |
| Test Code | 36942 |
| Additional Information |
The recommended alternative is test code-16220 Tick-borne Disease Antibodies Panel with Reflexes Please note: this code is contained in custom panels |